(S039) ALDH-Expressing Cancer Stem Cells Are Associated With Inferior Survival in Patients With Resected Pancreatic Adenocarcinoma Treated With Adjuvant Chemoradiation

Publication
Article
OncologyOncology Vol 28 No 4_Suppl_1
Volume 28
Issue 4_Suppl_1

In this study, we investigate the role of ALDH expression in predicting survival and patterns of disease recurrence in pancreatic adenocarcinoma patients treated with chemoradiation following pancreatectomy.

ALDH-Expressing Cancer Stem Cells Are Associated With Inferior Survival

Rachit Kumar, MD, Avani Dholakia, BS, Joseph Herman, MD, MS, Anirban Maitra, MD, Seung-Mo Hong, MD, William Matsui, MD, Christopher Wolfgang, MD, PhD, Dan Laheru, MD, Christine Iacobuzio-Donohue, MD, PhD, Zeshaan Rasheed, MD, PhD; Department of Radiation Oncology and Molecular Radiation Sciences, The Johns Hopkins University

Introduction: We and others previously identified aldehyde dehydrogenase (ALDH) activity as a marker of pancreatic cancer stem cells (or tumor-initiating cells). The presence of cancer stem cells (CSCs) has been associated with decreased survival and treatment resistance in pancreatic adenocarcinoma. In this study, we investigate the role of ALDH expression in predicting survival and patterns of disease recurrence in patients treated with chemoradiation (CRT) following pancreatectomy.

Methods: Tissue microarrays using pancreatectomy specimens from 1998–2002 at our institution were made, stained for ALDH1, and scored as ALDH-positive or ALDH-negative by two expert pancreatic cancer pathologists blinded to patient outcomes. Physician documentation and radiology reports were used to document patient follow-up information. Time to local failure (TLF), time to distant metastases (TDM), progression-free survival (PFS), and overall survival (OS) were analyzed using SPSS software.

Results: Previously, we found that ALDH expression was associated with worse OS in a cohort of 269 patients with resected pancreatic adenocarcinoma (Rasheed, JNCI 2009). From this original cohort, adjuvant treatment information was available for 87 patients with ALDH-negative tumors (48.6%) and 41 patients with ALDH-positive tumors (45.6%). In patients treated with adjuvant CRT, median OS was superior in the ALDH-negative cohort versus the ALDH-positive cohort (26.3 mo vs 18.2 mo; P = .011). Further, in patients treated with adjuvant CRT, ALDH-negative patients had statistically greater TLF, TDM, and PFS than their ALDH-positive counterparts (see Table). On multivariate analysis, ALDH-positive tumor staining (hazard ratio [HR] = 1.94; P = .004) and tumor grade (HR = 1.54; P = .041) predicted lower OS, and ALDH-positive tumor staining (HR = 1.83; P = .008), tumor grade (HR = 1.52; P = .038), and tumor size > 3 cm (HR = 1.65; P = .023) predicted decreased PFS.

Discussion: This study suggests that adjuvant CRT improves TLF, TDM, PFS, and OS in patients with localized pancreatic adenocarcinoma that is not enriched with ALDH-expressing CSCs. We are in the process of studying ALDH expression as a biomarker for predicting response to chemoradiation in patients with locally advanced pancreatic adenocarcinoma. Laboratory studies will help elucidate the mechanisms of treatment resistance in ALDH-expressing CSCs.

Proceedings of the 96th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(S002) Outcomes and Prognostic Factors of Stereotactic Body Radiotherapy for Soft Tissue Sarcoma Metastases
(S001) Limb-Sparing Surgery and Intraoperative Radiotherapy in the Treatment of Primary, Nonmetastatic Extremity and Limb-Girdle Soft Tissue Sarcoma
(S003) Disparities in Stage at Diagnosis and Survival in Adult Cancer Patients According to Insurance Status
(S004) Radiation Publications Underrepresented in High-Impact General Medical and Oncology Journals 
(S005) Adjuvant Radiotherapy in Stage II Endometrial Carcinoma: Is Brachytherapy Alone Sufficient for Local Control?
(S006) Extended-Field IMRT With Concomitant Boost for Node-Positive Cervical Cancer: Analysis of Regional Control Rate and Recurrence Pattern
(S007) Stereotactic Radiosurgery to the Brain With Concurrent BRAF Inhibitors for Melanoma Metastases
(S008) Use of Mobile Devices for Creation of Survivorship Care Plans
(S009) Two-Year Outcomes Following Triapine Radiochemotherapy for Cervical Cancer 
(S010) Prospective and Real-Time Data Analysis of Image-Guided Radiotherapy Across a Multinational Pediatrics Consortium: Methodology and Considerations 
(S011) Comparison of Toxicities and Outcomes for Conventional and Hypofractionated Radiation Therapy for Early Glottic Carcinoma
(S013) Adjuvant Radiation Therapy and Temozolomide for Anaplastic Gliomas: The Twelve-Year Washington University Experience
(S014) Gamma Knife Stereotactic Radiosurgery in the Treatment of Brainstem Metastases
(S015) Temporal Lobe Radionecrosis After Skull Base Radiotherapy: Dose-Volume Predictors 
(S012) Prognostic Value of Radiographic Extracapsular Extension in Locally Advanced Non-Oropharyngeal Head and Neck Squamous Cell Cancers
Recent Videos
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight the many advantages to attending the 42nd Annual Miami Breast Cancer Conference, with some additional tidbits to round out the main event.
Other ongoing urothelial cancer trials are assessing enfortumab vedotin–based combinations in the neoadjuvant setting.
Given resource scarcity, developing practice strategies for resource-constrained settings would require aid from commercial and government stakeholders.
Approximately 95% of those with a complete response to enfortumab vedotin plus pembrolizumab were alive after 2 years in the phase 3 EV-302 trial.
Thomas Powles, MBBS, MRCP, MD, highlighted fatigue, nausea, and peripheral neuropathy as toxicities observed with enfortumab vedotin plus pembrolizumab.
Large international meetings may facilitate conversations regarding disparities of care outside of high-income countries.
Related Content